About

Corporate finance and biotech are wary of each other.

On one side: predictability, control, traceability. On the other: high risk, long cycles, lumpy spending. Redmontis was designed at that intersection.

Mission

Give biotech executives back control of their cash, and the time that comes with it.

A biotech CEO juggles science, funding and a demanding board. Financial steering shouldn't cost them their days or hinge on a spreadsheet only they understand. They need to see their runway at any moment and respond fast, without turning into an analyst.

Generalist financial tools ignore clinical milestones and R&D disbursements. Spreadsheets can't take the load. Redmontis fills that gap with a single, traceable and defensible source of data, shared between the executive and their finance team.

Origin

Born in the field, not on a slide.

Redmontis didn't start as a software idea, but as an Excel model built by the founder of Redmontis, used under real-world biotech management conditions and refined over 5 years, board after board, raise after raise. Right where spreadsheets break the moment a trial slips or a grant moves three months out.

Biotech executives and CFOs used it for several months with their own data to improve its responsiveness and relevance before it became a SaaS. They observed its use and value under real-world conditions. Every screen grew out of that use, not from abstract functional logic.

From that battle-tested model, the Redmontis solution was born.

The founder

A tool written by the person who needed it.

Christophe Hubert

Founder & CEO · Redmontis

Former biotech CEO, expert in FP&A and financial strategy for biotechs. He lived through the cash decisions that make or break a biotech from the inside, then turned the tool he used into a product.

Redmontis did not come out of a market study: it is his own steering model, kept under real-world conditions, that his peers asked him to open up.

Running biotechsFinancial steering lived from the executive's chair, not from a consultancy.

FP&A and funding strategyRunway, fundraising scenarios, use of proceeds, board reporting.

5 years in the fieldA model refined board after board, raise after raise, on real data.

Tested by his peersUsed for several months by biotech executives and CFOs before it became a product.

contact@redmontis.com LinkedIn

Vision

Become the standard financial infrastructure for biotech.

What the Bloomberg terminal is to capital markets, Redmontis aims to be to biotech financial decision-making.

Precision above all

Defensible, traceable figures that stand up to a board or an auditor.

Designed, not adapted

Built natively for the constraints of biotech, not a generalist tool dressed up.

Institutional restraint

The voice of a senior CFO who knows their subject and doesn't have to sell themselves.

Target

Biotech CEOs and CFOs

Sector

Early-stage biotech, from Seed to Series B

Scope

Runway, scenarios, Use of Proceeds, CIR

Who it's for

First for the executive, then for their finance team.

The CEO sees their runway and decides without opening a file
The CFO or controller works on the same data
The board reads clear, consistent reporting
Not an accounting ERP, not a clinical data tool

Let's talk about your financial steering.

Biotech executive or finance lead, let's see how Redmontis fits into your day-to-day.